# Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies

> **NCT02224599** · PHASE1,PHASE2 · TERMINATED · sponsor: **Kiromic BioPharma Inc.** · enrollment: 3 (actual)

## Conditions studied

- Progressive Solid Malignancies
- Refractory Solid Malignancies
- Cancer

## Interventions

- **BIOLOGICAL:** TAPA-pulsed DC vaccine
- **DRUG:** Cyclophosphamide Pill
- **DRUG:** Imiquimod Topical Cream

## Key facts

- **NCT ID:** NCT02224599
- **Lead sponsor:** Kiromic BioPharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-07-28
- **Primary completion:** 2018-08-30
- **Final completion:** 2018-08-30
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Sponsor decision to terminate study due to poor accrual
- **Last updated:** 2020-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02224599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02224599, "Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02224599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*